What do systematic reviews say?

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 542 participants
  Low

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Steroids vs no specific treatment

It is very uncertain whether steroids changes complete remission Time frame: to 77 months compared with no specific treatment (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.44 [0.95, 2.19]
  1 study · 28 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 4.75]
  1 study · 22 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.13 [0.15, 0.4]
  1 study · 18 participants
  Very low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.93, 1.05]
  8 studies · 492 participants
  Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.01 [0.96, 1.05]
  4 studies · 269 participants
  Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids showed no clear difference in relapse Time frame: 6 to 12 months compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.73 [0.51, 1.03]
  7 studies · 422 participants
  Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: diabetes or hyperglycaemia compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.48 [0.19, 1.25]
  7 studies · 450 participants
  Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: obesity or Cushing's Syndrome compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.11 [0.02, 0.59]
  5 studies · 388 participants
  Low